iCAD, Inc. provides image analysis, workflow solutions, and radiation therapy for the early identification and treatment of cancer in the United States and internationally. It operates through two segments, Cancer Detection and Cancer Therapy. The company provides electronic brachytherapy (eBX) products, including Axxent eBx systems for the treatment of early stage breast cancer, endometrial cancer, cervical cancer, and skin cancer, as well as for treating other cancers or conditions where radiation therapy is indicated comprising intraoperative radiation therapy. It also offers digital mammography computer-aided detection (CAD) products, such as advanced image analysis and workflow solutions in breast imaging, which include PowerLook Mammo Detection, which detects and identifies suspicious masses and micro-calcifications; and PowerLook Advanced Mammography Platform, a computer server residing on a customer's network that receives patient studies from the imaging modality, performs CAD and density assessment analysis, and sends the CAD results to picture archiving and communication system and/or review workstations. In addition, the company's digital mammography CAD products comprise magnetic resonance imaging products to detect breast and prostate cancer; breast tomosynthesis systems; and advanced image analysis and workflow solutions in computed tomography (CT) colonography, including VeraLook that supports the detection of colonic polyps in conjunction with CT colonography. It serves hospitals, ambulatory care centers and free standing radiation oncology facilities, and other office-based uses through sales organizations, as well as through various original equipment manufacturer partners, distributors, and resellers. iCAD, Inc. has a strategic partnership agreement with Invivo Corp. The company was formerly known as Howtek, Inc. and changed its name to iCAD, Inc. in June 2002. iCAD, Inc. was founded in 1984 and is headquartered in Nashua, New Hampshire.
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryN/A
SectorComputer and Technology
Phone603-882-5200
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$25.62 million
Profitability
Miscellaneous
Employees95
Next Earnings Date2/27/2020 (Confirmed)
OptionableOptionable
iCAD (NASDAQ:ICAD) Frequently Asked Questions
What is iCAD's stock symbol?
iCAD trades on the NASDAQ under the ticker symbol "ICAD."
How were iCAD's earnings last quarter?
iCAD Inc (NASDAQ:ICAD) posted its earnings results on Wednesday, October, 30th. The technology company reported ($0.10) EPS for the quarter, meeting analysts' consensus estimates of ($0.10). The technology company earned $7.86 million during the quarter, compared to the consensus estimate of $7.43 million. iCAD had a negative return on equity of 76.99% and a negative net margin of 46.85%. View iCAD's Earnings History.
When is iCAD's next earnings date?
How can I listen to iCAD's earnings call?
iCAD will be holding an earnings conference call on Thursday, February 27th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.
What price target have analysts set for ICAD?
4 equities research analysts have issued 12-month target prices for iCAD's shares. Their forecasts range from $10.00 to $15.00. On average, they expect iCAD's share price to reach $13.50 in the next twelve months. This suggests a possible upside of 16.0% from the stock's current price. View Analyst Price Targets for iCAD.
What is the consensus analysts' recommendation for iCAD?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for iCAD in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for iCAD.
Has iCAD been receiving favorable news coverage?
Media coverage about ICAD stock has trended somewhat negative recently, InfoTrie Sentiment reports. InfoTrie ranks the sentiment of press coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. iCAD earned a media sentiment score of -1.8 on InfoTrie's scale. They also gave news articles about the technology company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the next few days. View News Stories for iCAD.
Are investors shorting iCAD?
iCAD saw a increase in short interest in the month of January. As of January 15th, there was short interest totalling 682,400 shares, an increase of 13.4% from the December 31st total of 601,500 shares. Based on an average daily volume of 102,800 shares, the days-to-cover ratio is presently 6.6 days. Approximately 4.0% of the company's stock are short sold. View iCAD's Current Options Chain.
Who are some of iCAD's key competitors?
Some companies that are related to iCAD include Intersect ENT (XENT), Orthofix Medical (OFIX), Cerus (CERS), MiMedx Group (MDXG), Orthopediatrics (KIDS), LeMaitre Vascular (LMAT), Anika Therapeutics (ANIK), Antares Pharma (ATRS), SurModics (SRDX), SI-Bone (SIBN), AngioDynamics (ANGO), Alphatec (ATEC), OraSure Technologies (OSUR), Inovio Pharmaceuticals (INO) and Utah Medical Products (UTMD).
What other stocks do shareholders of iCAD own?
Who are iCAD's key executives?
iCAD's management team includes the folowing people:
- Ms. Stacey M. Stevens, Pres (Age 51)
- Mr. Michael S. Klein, Exec. Chairman & CEO (Age 65)
- Mr. R. Scott Areglado, VP, Corp. Controller & Interim CFO (Age 55)
- Mr. Jonathan Go, Chief Technology Officer (Age 56)
- Ms. Annette L. Heroux, VP of Admin. (Age 62)
Who are iCAD's major shareholders?
iCAD's stock is owned by many different of institutional and retail investors. Top institutional investors include Renaissance Technologies LLC (3.11%), Parkman Healthcare Partners LLC (3.10%), EAM Investors LLC (1.81%), Geode Capital Management LLC (0.72%), Oxford Asset Management LLP (0.59%) and Essex Investment Management Co. LLC (0.45%). View Institutional Ownership Trends for iCAD.
Which major investors are selling iCAD stock?
ICAD stock was sold by a variety of institutional investors in the last quarter, including Essex Investment Management Co. LLC, Granite Investment Partners LLC, Oxford Asset Management LLP, Advisor Group Inc., Acadian Asset Management LLC and Sprott Inc.. View Insider Buying and Selling for iCAD.
Which major investors are buying iCAD stock?
ICAD stock was purchased by a variety of institutional investors in the last quarter, including Parkman Healthcare Partners LLC, Credit Suisse AG, Schonfeld Strategic Advisors LLC, EAM Investors LLC, IHT Wealth Management LLC, Charles Schwab Investment Management Inc., Renaissance Technologies LLC and Geode Capital Management LLC. View Insider Buying and Selling for iCAD.
How do I buy shares of iCAD?
Shares of ICAD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is iCAD's stock price today?
One share of ICAD stock can currently be purchased for approximately $11.64.
How big of a company is iCAD?
iCAD has a market capitalization of $225.47 million and generates $25.62 million in revenue each year. The technology company earns $-9,020,000.00 in net income (profit) each year or ($0.38) on an earnings per share basis. iCAD employs 95 workers across the globe.View Additional Information About iCAD.
What is iCAD's official website?
How can I contact iCAD?
iCAD's mailing address is 98 SPIT BROOK ROAD SUITE 100, NASHUA NH, 03062. The technology company can be reached via phone at 603-882-5200 or via email at [email protected]
MarketBeat Community Rating for iCAD (NASDAQ ICAD)
MarketBeat's community ratings are surveys of what our community members think about iCAD and other stocks. Vote "Outperform" if you believe ICAD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ICAD will underperform the S&P 500 over the long term. You may vote once every thirty days.
